Proteinuria changes in kidney disease patients with clinical remission during the COVID-19 pandemic.
Adult
Aged
Angiotensin-Converting Enzyme Inhibitors
/ therapeutic use
COVID-19
/ epidemiology
Female
Humans
Japan
/ epidemiology
Logistic Models
Male
Middle Aged
Odds Ratio
Proteinuria
/ complications
Remission Induction
Renal Insufficiency, Chronic
/ complications
Retrospective Studies
SARS-CoV-2
/ isolation & purification
Severity of Illness Index
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
31
01
2021
accepted:
08
04
2021
entrez:
23
4
2021
pubmed:
24
4
2021
medline:
8
5
2021
Statut:
epublish
Résumé
Data on how lifestyle changes due to the coronavirus disease 2019 (COVID-19) pandemic have influenced the clinical features of kidney disease patients remain scarce. This study retrospectively analyzed clinical variables in patients with stage G1-G4 chronic kidney disease (CKD) with complete or incomplete remission of proteinuria, who were managed in a nephrology outpatient clinic of a university hospital in Tokyo. The clinical variables during the COVID-19 pandemic (term 1, June-July 2020) were compared to those one year before the pandemic (term 0, June-July 2019). The urinary protein excretion (UPE) was used as the primary outcome measure. This study included 325 patients with stage G1-G4 CKD (mean age 58.5 years old, 37.5% female, 80.6% on renin-angiotensin aldosterone system inhibitors [RAASis], 12.0% on maintenance dose immunosuppression therapy) evaluated at term 0. The UPE at terms 0 and 1 was 247 (92-624) and 203 (84-508) mg/day [median (25th-75th percentile)], respectively; the value in term 1 was 18% lower than that in term 0 (p<0.001), with no marked difference in body weight, blood pressure, protein intake or urinary salt excretion. In multivariable analyses, incomplete remission of proteinuria in term 0 (odds ratio [OR] = 2.70, p = <0.001), RAASi use (OR = 2.09, p = 0.02) and decreased urinary salt excretion in term 1 vs. term 0 (OR = 1.94, p = 0.002) were identified as independent variables associated with reduced UPE in term 1 vs. term 0. No significant interactions between the variables were observed. In kidney disease patients receiving standard medical care from nephrologists, the UPE after the emergency declaration in relation to the COVID-19 pandemic was lower than before the declaration. The UPE reduction may be associated with reduced dietary salt intake during the pandemic in patients treated with RAASi for insufficient control of proteinuria. Our results support the current proposal to continue therapeutic approaches to these patients, which involve RAASi therapy along with optimizing dietary habits, even while dealing with the COVID-19 pandemic.
Sections du résumé
BACKGROUNDS
Data on how lifestyle changes due to the coronavirus disease 2019 (COVID-19) pandemic have influenced the clinical features of kidney disease patients remain scarce.
METHODS
This study retrospectively analyzed clinical variables in patients with stage G1-G4 chronic kidney disease (CKD) with complete or incomplete remission of proteinuria, who were managed in a nephrology outpatient clinic of a university hospital in Tokyo. The clinical variables during the COVID-19 pandemic (term 1, June-July 2020) were compared to those one year before the pandemic (term 0, June-July 2019). The urinary protein excretion (UPE) was used as the primary outcome measure.
RESULTS
This study included 325 patients with stage G1-G4 CKD (mean age 58.5 years old, 37.5% female, 80.6% on renin-angiotensin aldosterone system inhibitors [RAASis], 12.0% on maintenance dose immunosuppression therapy) evaluated at term 0. The UPE at terms 0 and 1 was 247 (92-624) and 203 (84-508) mg/day [median (25th-75th percentile)], respectively; the value in term 1 was 18% lower than that in term 0 (p<0.001), with no marked difference in body weight, blood pressure, protein intake or urinary salt excretion. In multivariable analyses, incomplete remission of proteinuria in term 0 (odds ratio [OR] = 2.70, p = <0.001), RAASi use (OR = 2.09, p = 0.02) and decreased urinary salt excretion in term 1 vs. term 0 (OR = 1.94, p = 0.002) were identified as independent variables associated with reduced UPE in term 1 vs. term 0. No significant interactions between the variables were observed.
CONCLUSION
In kidney disease patients receiving standard medical care from nephrologists, the UPE after the emergency declaration in relation to the COVID-19 pandemic was lower than before the declaration. The UPE reduction may be associated with reduced dietary salt intake during the pandemic in patients treated with RAASi for insufficient control of proteinuria. Our results support the current proposal to continue therapeutic approaches to these patients, which involve RAASi therapy along with optimizing dietary habits, even while dealing with the COVID-19 pandemic.
Identifiants
pubmed: 33891663
doi: 10.1371/journal.pone.0250581
pii: PONE-D-21-03368
pmc: PMC8064597
doi:
Substances chimiques
Angiotensin-Converting Enzyme Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0250581Commentaires et corrections
Type : ErratumIn
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest in association with the present study.
Références
Hypertens Res. 2020 Oct;43(10):1028-1046
pubmed: 32737423
Kidney Int. 2015 Dec;88(6):1392-1401
pubmed: 26287314
Hypertension. 2020 Aug;76(2):e13-e14
pubmed: 32458694
Am J Kidney Dis. 2014 Sep;64(3):383-93
pubmed: 24913219
Lancet Diabetes Endocrinol. 2014 May;2(5):385-95
pubmed: 24795252
Am J Med. 1974 Jan;56(1):71-82
pubmed: 4588641
N Engl J Med. 1994 Mar 31;330(13):877-84
pubmed: 8114857
Nat Rev Nephrol. 2012 Mar 06;8(5):301-6
pubmed: 22391456
Hypertens Res. 2020 Nov;43(11):1257-1266
pubmed: 32820236
PLoS One. 2020 Jun 11;15(6):e0234292
pubmed: 32525881
Lancet. 2020 May 30;395(10238):1705-1714
pubmed: 32416785
Hypertension. 2019 Sep;74(3):564-571
pubmed: 31280649
N Engl J Med. 2020 Jun 18;382(25):2441-2448
pubmed: 32356628
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
J Am Soc Nephrol. 2012 Jan;23(1):165-73
pubmed: 22135311
Circ J. 2002 Nov;66(11):987-92
pubmed: 12419927
PLoS One. 2017 Nov 2;12(11):e0187607
pubmed: 29095887
Kidney Int. 2012 Aug;82(3):330-7
pubmed: 22437412
Am J Kidney Dis. 2009 Jun;53(6):982-92
pubmed: 19339088